Candidate biomarker assessment for pharmacological response.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
26
03
2020
revised:
23
06
2020
accepted:
26
06
2020
pubmed:
12
7
2020
medline:
12
7
2020
entrez:
12
7
2020
Statut:
ppublish
Résumé
Using the information from our CellMiner (https://discover.nci.nih.gov/cellminer/) and CellMinerCDB (https://discover.nci.nih.gov/cellminercdb/) web-based applications, we identified 3978 molecular events with significant links to pharmacological response for genes that are either targets, biomarkers, or have established causal linkage to drugs. Molecular events included DNA copy number, methylation and mutation; and transcript; and whole or phospho-protein expression for the NCI-60 human cancer cell lines. While all forms of molecular data were informative in some (gene-drug) pairings, the type of significantly linked molecular events was found to vary widely by drug. Some forms of molecular data were found to have more frequent significant correlation than others. Leading were phosphoproteins as measured by antibody (31%), followed by transcript as measured by microarray (16%), and total protein levels as measured by mass spectrometry or antibody (14%). All other measurements ranged between 5 and 11%. Data reliability was underscored by concordant results when using differing drugs with the same targets, as well as different measurements of the same molecular parameter. The significance of correlations of the various molecular parameters to the pharmacological responses provides functional indication of those parameters that are biologically relevant for each gene-drug pairing, as well as comparisons between measurement types.
Identifiants
pubmed: 32652468
pii: S1936-5233(20)30322-3
doi: 10.1016/j.tranon.2020.100830
pmc: PMC7348063
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100830Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Breast Cancer. 2007;14(2):156-62
pubmed: 17485900
Trends Cancer. 2017 Jan;3(1):2-6
pubmed: 28603778
Clin Cancer Res. 2019 Nov 15;25(22):6581-6589
pubmed: 31227499
Future Oncol. 2012 May;8(5):509-23
pubmed: 22646766
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34
pubmed: 14623978
Gynecol Oncol. 2012 Mar;124(3):569-74
pubmed: 22037316
Cancers (Basel). 2019 Dec 05;11(12):
pubmed: 31817473
Pharmacol Ther. 2019 Sep;201:94-102
pubmed: 31128155
iScience. 2018 Dec 21;10:247-264
pubmed: 30553813
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
iScience. 2019 Nov 22;21:664-680
pubmed: 31733513
Metabolism. 2015 Mar;64(3 Suppl 1):S16-21
pubmed: 25468140
Mol Cell Proteomics. 2018 Jun;17(6):1245-1258
pubmed: 29531020
Cancer Res. 2019 Jul 1;79(13):3514-3524
pubmed: 31113817
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5
pubmed: 22927417
Yonsei Med J. 2019 Jun;60(6):525-534
pubmed: 31124335
Leukemia. 2000 Sep;14(9):1533-59
pubmed: 10994999
Hum Mol Genet. 2016 Oct 1;25(R2):R166-R172
pubmed: 27538422
Trends Cancer. 2018 Jan;4(1):3-6
pubmed: 29413420